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The association o[ a  variety of immune disorders and human leukemia and lyre- 
photon  is well established. Aberrations such  as anergy  in  active Hodgkin's disease 
(1) and hypogammaglobulinemia in chronic lymphocytic leukemia (2)  are clearly the 
result of malignant disease of the lymphoreticular tissues. In other instances, however, 
the defect in immunity appears to precede by months or even years the subsequent 
neoplasia. Thus, leukemia and lymphoma have developed during the course of auto- 
immune  hemolytic  anemia  (3),  Sj6gren's  syndrome  (4),  and  congenital  agamma- 
globulinemia (5). 
A  mouse model has been used to study the mechanism by which an immune dis- 
turbance can lead to the development of lymphoreficular malignancy. In this experi- 
mental  system,  developed by  Schwartz  and  Beldotti  (6),  a  graft-vs.-host reaction 
(GVHR) 1 is induced in young adult F1 hybrid mice by the administration of spleen 
cells from one of the parental strains. The recipients have the same antigens as the 
grafted cells and do not reject them, whereas immunologically competent cells in the 
inoculum are stimulated by those antigens in the FI host which are derived from the 
other parent.  After a  latent period of some months,  a  proportion of these  GVHR 
mice develop lymphoreticular tumors (7). 
The experiments described here were designed to test the possibility that the im- 
mune  disturbance associated with the  GVHR  activates a  virus with oncogenic po- 
tential,  and  that  this  is the agent  responsible for  subsequent  tumor  development. 
There is precedent for this viral activation concept in the work of Kaplan (8), who 
established that thymic lymphomas can be induced in the low leukemia C57BL mouse 
strain by an irradiation-activated murine leukemia virus (MuLV). 
In the present study,  the  GVHR was induced in  (BALB/cl  X  A/J)F, and 
(BALB/cJ  X  C57BL/6J)F~  hybrid mice by the  administration of BALB/cJ 
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spleen cells.  Both  the  Fl hybrid  strains,  as well as the BALB/c  strain,  have  a 
low spontaneous  incidence of lymphoreticular malignancy  (7,  9). Data  are pre- 
sented  which  demonstrate  that  (a)  cell-free  extracts  (CFEs)  prepared  from 
GVHR  mice are oncogenic; (b)  these extracts contain infectious MuLV  and/or 
group-specific  (gs),  complement-fixing (CF)  MuLV  antigen;  (c)  serially passed 
CFEs  originating from a  GVHR-induced  tumor contain infectious MuLV  and 
CF MuLV  antigen.  When these serially passed  CFEs are injected into recipient 
mice,  they cause lymphoreticular  tumors,  which also contain infectious MuLV 
and  CF MuLV  antigen,  as well as characteristic  C-type particles.  Since CFEs 
from normal control mice matched for strain, age, and sex are not oncogenic and 
contain  no  CF  antigen  or  infectious  virus,  it  seems  clear  that  the  GVHR  is 
"turning on" an MuLV  which is tumorigenic. 
Materials and Methods 
Animals.--BALB/cJ,  C57BL/6J, and  (BALB/cJ X  A/J)F1  hybrid  mice were  obtained 
from  the  Jackson  Laboratory,  Bar  Harbor,  Maine.  National  Institutes  of Health  (NIH) 
Swiss mice were obtained from the Animal Production Section of NIH. (BALB/cJ X A/J)F1 
and (BALB/cJ X  C57BL/6J)F1 hybrid mice were bred in our own laboratory.  (BALB/cJ X 
A/J)FI  and  (BALB/cJ X  C57BL/6J)F1  hybrid  mice  are  hereafter  referred  to  as  CAF1 
and CB6F1 mice, respectively. 
Induction of GVHR.--A GVHR was induced in 6-wk-old  male CAF1 and CB6FI mice by 
the administration  of spleen ceils from 6-8-wk-old male BALB/cJ mice.  Mice of each  FI 
hybrid strain received, in four weekly intraperitoneal doses,  a total of approximately 200  X 
10  n spleen cells, prepared as previously described (10). 
Preparation of CFEs.--CFEs were prepared from tumor tissue, or from a pool of reticular 
tissues,  in non-tumor-beating mice. This pool consisted of spleen, mesentetic and other lymph 
nodes, thymus, portions of liver and kidney, and bone marrow from the femurs. For in vivo 
inoculation, the tissues were processed according to the method used by Moloney to extract 
MuLV (11). A 10% suspension  of finely minced tissue in 0.153 M potassium citrate containing 
1.5 mg hyaluronidase/100 ml was allowed to digest at room temperature,  then was homoge- 
nized in  a  Duall tissue  grinder  0Kontes  Glass  Co.,  Vineland,  N.J.).  The homogenate was 
cleared of nuclei and cell fragments by two 20-rain  centrifugations at 2,300 g/rain. The super- 
natant was centrifuged at  10,000 g for 1 rain to remove mitochondrial fragments and aggre- 
gated particulates,  and at 30,000 g for 60 rain to sediment the MuLV. The pellet was resus- 
pended in a  volume of 0.05  M  pH 6.8 sodium citrate buffer adjusted so that  each milliliter 
of suspension  was equivalent to 1 g of tissue. The suspension was clarified by further centri- 
fugation at 5,000 g and the supernatant  was inoculated into a litter of syngenelc mice within 
36 h  of  birth. Each  animal  received 0.05  ml of supernatant  intraperitoneally. For in vitro 
testing, tissues were finely minced in Eagle's minimal essential medium with 100 U penicillin 
and 100/zg streptomycin/ml. 10-20%  suspensions  were homogenized in a Duall tissue grinder 
and clarified twice by centrifugation at 2,300 g/min for 20 rain.  Supernatants  were stored  at 
--  60°C. 
Autopsies.--All animals killed for preparation  of CFEs were autopsied,  as  were all re- 
cipients of CFEs. The latter were killed at 18 mo of age or, if tumors developed, before then. 
The reticular tissues  of all animals autopsied were routinely sampled for histological exam- 
/nation, as were other tissues showing macroscopic abnormalities. Tissue samples were fixed 
in  10~o buffered formalin,  and  sections were cut  and  stained  with hematoxylin and  eosin. 
Lymphoreticular  neoplasms  were  classified  according  to  Dunn  (12). 
Infectious MuLV Assay.--CFEs were tested for infectious MuLV following the UV-XC ARMSTRONG,  RLIDDLE,  LIPMAN,  AND  RICHARDS  1165 
procedure  described  by  Rowe  and Pincus  (13).  NIH  Swiss and  BALB/cJ  mouse  embryo 
cells,  prepared in our laboratory and seeded into 60 X  15 mm Falcon plastic Petri dishes 
(Falcon Plastics, Oxnard, Calif.), were treated with 25/zg/ml DEAE-dextran, then inoculated 
with 0.1 ml of serial dilutions of the test extracts.  1 wk later, the mouse embryo cells were 
irradiated with 1,000-1,500 ergs/mm  2 of ultraviolet light, and 1 )< 106 XC cells were added. 
The cultures were fixed and stained with Giemsa 34  days later. Areas of syncytial formation 
with giant cells, in the XC cell sheet overlying foci of MuLV infection, were counted as plaques 
under the microscope. Titers were expressed as logl0 plaque-forming units  (PFU)/0.2  g  of 
tissue.  Each CFE was tested on both NIH Swiss  and BALB/cJ mouse embryo cells.  Each 
set of XC assays included two positive controls, namely, N-tropic virus WN1802N  and B- 
tropic virus WN18023, kindly provided by Dr. Wallace P. Rowe. 
Complement Fixation  Test for gs MuLV Antigen.--CFEs  were  tested  in  Dr.  Robert  J. 
Huebner's laboratory for the presence of gs antigen using a  micro-complement fixation test 
(14).  The tissue extracts were incubated with murine sarcoma virus pool 30 serum  (pooled 
sera from Fischer rats with transplanted sarcomas induced by Moloney murine sarcoma virus) 
in the presence of complement. The amount of complement fixed was measured in a  sheep 
erythrocyte hemolytic system. Double dilutions to 1 in 16 were carried out for each extract. 
Electron Microscopy.--Portions of splenic tumor and normal control spleen were minced 
into 1 mm cubes. These were fixed in 2.5% glutaraldehyde with 0.2 M  sucrose in 0.1 M  so- 
dium phosphate buffer, and postfixed in buffered 1% osmium tetroxide. After dehydration, 
the samples were embedded in Epon-Araldite (15).  Sections from the resulting blocks were 
stained with 3.5%  uranyl acetate in 50%  ethanol and lead  citrate  (Reynolds' stain)  (16). 
Control spleen and tumor cells were examined at  X  20,000 magnification and micrographs 
were  taken at  both this and  X  36,000  in  a  Philips EM-200  electron microscope  (Philips 
Electronic Instruments, Mount Vernon, N. Y.) operating at an accelerating voltage of 60 kV. 
RESULTS 
Oncogenicity of CFEs from Mice with the GVHR.-- 
Experimental group:  A total of 29 CAF1 mice with the GVHR were killed at 
intervals from 3 days to 15 mo after the first injection of parental spleen cells 
(Fig. 1)  A CFE prepared from each of these animals was inoculated into a litter 
of newborn syngeneic mice, which were then observed for tumor development 
over the ensuing 18 too. Of the 29 CFEs prepared,  12  (41.4%)  were positive; 
i.e.,  lymphoreticular tumors developed in one or more littermate  recipients of 
each CFE within the 18 mo observation period. The oncogenic CFEs were from 
donors killed at all stages of the GVHR,  the earliest from an animal  10 days 
after the first injection of parental cells (Table I). However, the percent of posi- 
tive CFEs was greater among donors killed late in the GVHR. Thus, 5 of 16 
(31.3 %) CFEs from mice killed within 5 mo of GVHR induction were positive; 
1 of 5  (20%)  CFEs from mice killed 6-11 mo after GVHR induction was posi- 
tive; and 6 of 8 (75 %) CFEs from mice killed 12-15 mo after GVHR induction 
were positive (Table II). 25 of the 29  animals used as CFE donors showed no 
evidence of lymphoreticular tumors, four had a reticulum cell neoplasm (RCN), 
type B, involving the spleen, and/or lymph nodes, and Peyer's patches. Three 
of the four CFEs prepared from tumor-bearing mice were oncogenic (Table I). 
Lymphoreticular  tumors developed in recipients of CFEs  only after  a pro- 
tracted latent period; with one exception, all tumors were detected in recipients 1166  IMMUNOLOGICAL  ACTUv~ATION  OF  MURINE  LEUKEMIA  VIRUS 
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Fio.  1. Tumor induction by CFEs from CAF1 mice with the GVHR. The blocks represent 
the number of CFEs inoculated into newborn syngeneic mice; the hatched portions indicate 
the number of CFEs associated with the subsequent development of lymphoreticular tumors 
in one or more littermate  recipients.  The number above the blocks is the total  number of 
weaned recipient mice. The abscissa gives the time in months at which the donors of the CFEs 
were killed after induction of the GVHR. 
TABLE  I 
Oncogenic CFEs: Details of Donor and Recipient 3Iice 
Time at which  No. of mice 
Donor of CFE  donor was killed after  developing tumors/  Age at which tmnor  total no. of weaned  developed in recipient(s)  induction of GVHR*  recipients 
Non-tumor-bearing CAF1 
Non-tumor-bearing CAF1 
Non-tumor-bearing CAF1 
Non-tumor-bearing CAF1 
Non-tumor-bearing CAF1 
Non-tumor-bearing CAF1 
Non-tumor-bearing CAF1 
10 days  1/5  15 mo 
19 days  2/9  17 too,  18 mo 
22 days  1/7  18 mo 
40 days  1/4  18 mo 
3 mo  1/8  18 mo 
9 mo  1/2  18 mo 
12 mo  3/6  16 mo, 16 mo, 
18 mo 
Tumor-bearing CAF1  13 mo  I/3  18 mo 
Tumor-bearing CAF1  13 mo  1/2  18 mo 
Tumor-bearing CAF1  14 mo  2/4  15 mo, 15 mo 
Non-tumor-bearing CAF1  14 mo  1/4  12 wk 
Non-tumor-bearing CAFt  15 mo  2/11  17 mo, 18 mo 
* Day 0,  1st injection of parental spleen cells. ARMSTRONG,  RUDDLE,  LIPMAN, AND  RICHARDS 
TABLE  II 
Oncogeniclty of  CFEs from  GVHR  and  Control Mice 
1167 
GVHR group  Control group 
No. of positive CFEs  12  1 
(41.4%)  (6.3%)  Total no. of CFEs  29  16 
No. of positive CFE recipients  17  1 
(11.5%)  (1,2%)  Total no. of CFE recipients  148  84 
No. of positive CFEs with tumors 
developing in two or more littermates 
Total no. of positive CFEs 
No. of positive CFEs 
Total no. of CFEs using donors up 
to 7 mo of age 
No. of positive CFEs 
Total no. of CFEs using donors 
between 8 and 13 mo of age 
No. of positive CFEs 
Total no. of CFEs using donors 
between 14 and 18 mo of age 
4  0 
12  (33.3%)  ~  (0%) 
5  1 
i6  (31.3%)  ~  (14.3%) 
1  0 
g  (20%)  g  (0%) 
6  0 
(75%)  ~  (0%) 
between  15  and  18 mo of age  (Table I). In addition, the tumors were usually 
found in only one or two members of a  recipient litter, giving a  significant but 
low overall tumor incidence for all recipients (ll.S %).  However, tumors arose 
in two or more littermates in one-third of positive CFEs (Table II). All recipient 
lymphoreticular tumors were RCNs of the same type which occur in the GVHR 
mice (7) and involved the same primary tissues, namely, spleen, lymph nodes, 
and Peyer's patches. 
Control group:  A  total of 16 normal CAF~ male mice, ranging  in age from 2 
to 18 mo  (Table II), were used as donors of CFEs, which were then tested  for 
oncogenicity in exactly the same way as those prepared from GVHR  animals. 
Only  I  of a  total of 84  (1.2 %)  recipients developed a  lymphoreticular tumor. 
This animal was one of a weaned litter of six that received at birth a  CFE pre- 
pared from a  3-mo-old control donor. The tumor developed when the recipient 
was 12  mo old. 
Presence of Infectious MuL V and CF MuL V Antigen in CFEs from Mice with 
the GVHR.-- 
Experimental group:  14 CFEs prepared from a  total of 23 CAFx mice killed 
at intervals after the induction of the GVHR were tested for infectious MuLV 
using the XC  assay (Table III). Each extract was assayed on both NIH  Swiss 
and  BALB/cJ  mouse  embryo  cells. Nine  of  these  extracts were  obtained  by 1168  IM~£UNOLOGICAL  ACTIVATION  O1  ~  MURINE  LEUKEML~  VIRUS 
pooling tissue from two donors, five were prepared from single donors. The XC 
test was positive in 8 of the 14 (57.1%) CFEs. Four of eight (50%) CFEs pre- 
pared from mice killed within 9  mo of GVHR induction contained N-tropic  2 
virus in low  titer (1.0-1.3 log10 PFU/0.2 g  tissue). Four of six (66.7 %)  CFEs 
from mice killed 11-14 mo after induction of the  GVHR contained B-tropic  3 
virus in higher titers (1.3-3.9 log,0  PFU/0.2 g  tissue).  7 of the  14 CFEs were 
also  tested for the presence of CF MuLV antigen (Table IV), and 3  of these 
TABLE  IlI 
MuLV Tilers in Tissues of CAF1 GVHR Mice 
CFE no.  No. of donors 
Time at which donor(s) 
killed after GVHR 
induction 
MuLV liter (log10 PFU/0.2 g) 
on mouse embryo cells of: 
NIH Swiss*  BALB/cJ:~ 
1  2  10 days  Neg§  Neg 
2  2  10 days  Neg  Neg 
3  2  21 days  Neg  Neg 
4  2  6 wk  1.0  Neg 
5  2  6 wk  Neg  Neg 
6  2  3 mo  1,0  Neg 
7  2  5 mo  1.3  Neg 
8  1)!  9 mo  1.0  Neg 
9  1  11 mo  Neg  Neg 
10  ll~f  11 mo  Neg  1.3 
11  2  13 mo  Neg  3.9 
12  2  13 mo  Neg  2.5 
13  1  14 mo  Neg  Neg 
14  l[l  14 mo  Neg  3.1 
* More susceptible to infection by N-tropic virus. 
~More susceptible to infection by B-tropic virus. 
§Neg,  <101. 
/iTumor-bearlng animal. 
(42.391)  contained significant titers of  the  antigen (1:4  and over).  All  three 
CFEs positive for CF antigen were prepared from tumor-bearing mice late in 
the GVHR and all three were also positive in the XC test. 
Conlrol group:  Five CFEs from normal CAFI male mice were tested for in- 
fectious virus on both NIH Swiss and BALB/J mouse embryo cells,  and for 
CF antigen. One of these extracts was prepared from two 9-wk-old animals; the 
rest came from single donors, two of which were 18 mo old and two others, 24 mo 
old. In none of these was either infectious virus or CF antigen detected (Table 
IV). 
2 Growing preferentially on NIH Swiss mouse embryo cells. 
3 Growing preferentially on BALB/cJ mouse embryo cells. ARMSTRONG,  RUDI)LE,  LIPMAN,  AND  RICHARDS  1169 
TABLE IV 
MuLV and CF Antigen  Titers in Tissues of CAF1 GVHR and Control Mice 
No. of  Age of 
CFE no.  donors  donor(s)  CF antigen titer/0.2 g 
MuLV titer (tog10 
PFU/0.2 g) on 
mouse embryo cells of: 
NIH Swiss  BALB/cJ 
GVHR group 
4  2  3 mo  <1:2  1.0  Neg* 
7  2  7 mo  <1:2  1.3  Neg 
8  1~  11 rno  1:8  1.0  Neg 
9  1  13 mo  < 1  : 2  Neg  Neg 
10  1~  13 mo  1:4  Neg  1.3 
13  1  16 mo  < 1  : 2  Neg  Neg 
14  1~  16 mo  1:16 or >§  Neg  3.1 
Control group 
N1  2  9 wk  < 1  : 2  Neg  Neg 
N2  1  18 mo  < 1  : 2  Neg  Neg 
N3  1  18 mo  < 1  : 2  Neg  Neg 
N4  1  24 mo  < 1  : 2  Neg  Neg 
N5  1  24 mo  < 1  : 2  Neg  Neg 
* Neg, <10 I. 
Tumor-bearing animal. 
§ Dilutions only taken out to 1 in 16. 
Serial Passage In Vivo of CFEs from Mice with the GVHR. --The oncogenicity 
of the GVHR-activated MuLV has been reproduced in two separate serial pass- 
age experiments. In the first experimemt, a  CFE prepared from a non-tumor- 
bearing CAF1 mouse 15 mo after induction of the GVHR was injected into a 
litter of newborn syngeneic mice. An RCN developed at 17 and 18 mo of age, 
respectively, in 2 of 11  (18.2%)  weaned recipients. A  CFE prepared from the 
17-too-old tumor-bearing mouse caused the same type of tumor in second-pass- 
age CAF1 mice, also injected at birth. Three of six (50%) weaned littermate re- 
cipients developed an RCN, after 11 mo in one, and at 18 mo of age in the other 
two. 
In the second experiment, involving CB6F~ mice, RCNs have arisen in three 
transplant generations of syngeneic animals injected at birth with CFEs (Fig. 
2). A  cell suspension prepared from an RCN arising in a  CB6F1 mouse 12 mo 
after GVHR induction  was injected into a litter of 2-wk-old syngeneic mice. The 
tumor grew out readily in all recipients within 5 wk, and a  CFE of this trans- 
planted tumor was prepared from a 6-wk-old male animal. The CFE was inocu- 
lated into a litter of newborn CB6F1 mice and caused RCNs in at least six of the 
eight weaned recipients after a latent period ranging from 10 to 18 mo (mean, 
15 too). Extracts from two of these second-transplant generation tumors were 
tested for CF antigen, which was found in both in a titer of 1 : 8. In addition, one 
of these extracts was assayed for infectious virus, and was shown to contain B- 1170  B{MUNOLOGICAL  ACTIVATION  OY  1VIURINE  LEUKEMIA.  VIRUS 
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FIo.  2.  Oncogenicity of  GVHR-activated  MuLV in serial passage in vivo.  Mouse with 
lymphoreticular tumor, In; normal mouse, [] ; mouse dead of undetermined cause, kirk; mouse 
dead of nontumor cause, A. A tumor cell suspension prepared from a reticulum cell neoplasm 
arising in a CB6F1 mouse 12 mo after GVHR induction was injected intraperitoneally into a 
litter of 2-wk-old syngeneic infant mice (first-passage recipients). The RCN grew out readily 
in all recipients and a  CFE  of the transplanted tumor was prepared from a  6-wk-old male 
mouse.  This extract caused RCNs in at least six of eight syngeneic mice injected at birth 
after a  latent period ranging from  10  to  18  mo.  CFEs  prepared from  two  tumor-bearlng 
second-passage mice  both caused  RCNs  in  thlrd-passage recipients; at  least  9  of  14  mice 
developed tumors after a  mean latent period of 13 too. RCNs also developed in six of seven 
fourth-passage  recipients  of  a  CFE  prepared  from  a  non-tumor-bearing 3-too-old  third- 
generation animal, and in two of five mice that received a  CFE of a  thlrd-generation RCN. 
CFEs  prepared  from  representative RCNs  arising  in  second-,  third-,  and  fourth-passage 
recipients were examined for CF  antigen and/or infectious MuLV and C-t}?e  particles as 
indicated. CF, complement-fixing MuLV antigen titer; XC(N),  titer of infectious MuLV on 
NIH S~iss mouse embryo cells; XC(B), titer of infectious MuLV on Bz~LB/cJ mouse embryo 
cells. Titers of infectious MuLV are expressed as lOgl0 PFU/0.2 g of tissue. N, normal mouse; 
UC, mouse dead of unrelated cause; EM +, C-type particles seen during electron microscopy. 
tropic virus in a  titer of 3.4 log~0  PFU/0.2  g  tissue.  CFEs  prepared  from  two 
other second-transplant  generation  RCNs  were  inoculated  into  separate  new- 
born litters.  Third-transplant  generation RCNs  have developed  among  recipi- 
ents of each extract. At least 9  of a  total of 14 weaned third-passage recipients 
4MO  5MO  6MO  IIMO  12M0  ~3MO  5MO  3MO  I2MO  15MO  16M0  f7MO  17MO  17MO 
U  U  HI  n 
N  RCN  N  RCN  RCN  RCN  N  N  RCN  ?  RCN  RCN  RCN  RCN 
CFE  CFE  CFE  CFE 
CFI;16  CF [:16 
XC(B)2.6  XC(B)I-3 
2MO  2MO  12MO  12MO  12MO  9MO  9MO  IIMO  12MO  12MO  BMO  13MO 
N  U  ~  n  ~  ~ 
uc  UC  ?  RCN  RCN  1  RCN  RCN  RCN  RCN  RCN  RCN 
CFE  CFE  EM+  EM+ 
CFIq6  CF I:{6  CFE  CFE 
XC(N)-  XC(N)-  XC(N)- 
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developed lymphoreticular tumors within 17 mo, the earliest tumor being de- 
tected at 5 mo (mean latent period,  13 mo). Two third-transplant generation 
tumors (one from each litter) were tested for infectious virus and CF antigen. 
Both contained B-tropic virus in titers of 2.6 and 1.3 lOgl0 PFU/0.2 g tissue, re- 
spectively, and both had high titers of CF antigen (1 : 16 or greater). CFEs pre- 
pared from two third-passage mice for in vi~o inoculation and injected into two 
separate  newborn  litters  have  also  caused  lymphoreticular  tumors  in  both 
groups of mice  (mean latent period,  12  mo).  One of these  third-into-fourth- 
generation experiments is of particular interest in that the CFE injected was 
prepared from a third-passage CB6F1 mouse killed at the age of 3 too, at which 
time no macroscopic or microscopic evidence of tumor was detected. Inoculation 
of a CFE prepared from the reticular tissues of this animal has resulted in the 
development of RCNs in six of seven weaned recipients within the 13 mo that 
have since elapsed (mean  latent period,  12  mo).  Extracts from two of  these 
fourth-generation tumors were  tested for CF  antigen,  which was  detected in 
both extracts in high titer  (1:16 or greater).  One of these extracts was  also 
tested for infectious virus, but was negative on both NIH Swiss and BALB/cJ 
mouse embryo cells.  However, extracts from two other RCNs arising in litter- 
mates contained B-tropic MuLV in titers of 3.5 and 2.8 log10 PFU/0.2 g tissue, 
respectively. 
Splenic  tumors from the  two  fourth-passage  recipient mice just  described 
were examined in the electron microscope. Although most of the cells were in 
good condition, they contained swollen and internally disrupted mitochondria 
(Fig. 3 a). Some cells showed granular electron-opaque inclusions (Fig. 3 b). 
Particles with the structural characteristics of MuLV (17,  18) were readily 
found and fairly uniformly distributed throughout the tissues examined. The 
majority of the virions were found extracellulafly (Figs. 3 a, 3 b, 4 a, 4 e). Par- 
ticles were seen in various stages of budding from the cell membrane (Figs. 3 b, 
4 b, 4 c) and a few were found budding into or completely bounded by cytoplas- 
mic vacuoles (Figs. 3 a, 4 d). The virions were round with a diameter ranging 
from 90 to 115 nm (mean, 104 nm). The budding or free virions were bounded by 
a trilaminar envelope with small, irregular projections on its surface (Figs. 4  a, 
4  e). The nucleoid of the virions was surrounded by two moderately  electron- 
opaque shells,  the inner shell being more electron-opaque than the outer shell 
(Figs. 4 b, 4 e). The center of newly formed "immature" particles was electron- 
lucent (Figs. 4 a, 4 e). In the more "mature" virions, the central area was con- 
densed and denser (Fig. 4  d). Virions were not found  in  the nucleus,  and no 
other types of viral particles were seen in any of the tissues examined. 
Co~ztrol mice:  CFEs were prepared from each of four normal, uninjected, 18- 
mo-old male CB6F1 mice. All four extracts were negative for infectious virus on 
both NIH Swiss  and BALB/cJ mouse embryo cells and negative (less  than a 
titer of 1:2) for CF antigen. 
Normal splenic tissue from a control 12-mo-old male CB6F1 mouse was also 1172  IMMUNOLOGICAL  ACTIVATION  OF  MURINE  LEUKEMLA.  VIRUS 
FIG. 3. Reticulum cell neoplasm of spleen in 12-mo-old CB6F1 mice.  X  70,000.  Bar repre- 
sents 100 nm.  (a) Two virus particles (v) are shown; one is in a  forming cytoplasmic vacuole, 
the  other  is  extracellular.  A  swollen  and  disintegrating mitochondrium  (m),  as well  as  an 
empty vacuole, can be seen in the cytoplasm. The cell  nucleus (n) is in the upper right  corner 
of the micrograph. (b) Extracellular virus particles, and virus budding from the cell membrane. 
A  cytoplasmic inclusion (in) is present in an adjacent  cell. ARMSTRONG,  RUDDLE,  LIPY[AN,  AND  lZlCHARDS  1173 
FIG.  4.  C-type particles in  the splenic reticulum cell neoplasm of 12-mo-old CB6F1 mice. 
>(  120,000.  Bar  represents 100  nm.  (a)  Group  of at  least  three virions in  the extracellular 
space. One is still in the process of budding (g). Small irregular projections can be seen on the 
surface of an adjacent particle (arrow).  (b) Budding virlon almost free of the cell membrane. 
(c)  Particle in an earlier stage of budding, showing completion of the envelope (arrow) while 
the particle is still attached to the cell. (d) Virion formed in a cytoplasmic vacuole. The mate- 
rial in the center of the particle is beginning to condense. (e) This free but "immature" virion 
has an electron-lucent center surrounded by two concentric shells, the inner of which is more 
electron-opaque than  the  other.  It  is  bounded  by an  envelope whose surface shows small, 
irregular spikes. 
examined in the electron microscope. The cells contained normal mitochondria 
and no virions. 
DISCUSSION 
A  substantial  proportion  of mice in  which  a  protracted  GVHR is induced 
subsequently  develop lymphoreticular  tumors  (7,  9).  It has  been previously 
shown  that MuLV is  activated in  the  GVHR  (19),  and  that  CFEs prepared 
from GVHR mice are oncogenic (20). In order to establish the causal role of the 
virus, it is necessary to show that (a) there is an increase in MuLV titer in mice 
with the GVHR (b) CFEs prepared from GVHR animals both before and after 
the  onset of tumors contain MuLV,  and  (c)  such  CFEs are capable of trans- 
mitting tumors to recipient mice. 
The studies of Hirsch et al.  (19)  using the same CAF~ GVHR model as that 
described in this report, have demonstrated that MuLV may be recovered from 
the spleens of mice observed in the 4 mo after the induction of the GVHR. No 1174  IMMUNOLOGICAL ACTIVATION OF  MURINE  LEUKEMIA  VIRUS 
virus was recovered from normal control animals examined up to 6 mo of age. 
Since the presence of MuLV per se in the GVHR does not establish its causal 
role in the genesis of the lymphoreticular tumors, we prepared CFEs from CAF1 
GVHR animals and tested these for their ability to reproduce the same tumors 
in normal syngeneic mice. Preliminary findings already reported (20) have been 
extended.  12 of 29 (41.4~7~) such extracts caused lymphoreticular tumors in re- 
cipient mice, while only 1 of 16 (6.3 ~) CFEs prepared from a control group of 
mice matched for strain, age, and sex did so. A striking feature of these experi- 
ments is that whereas less than 30% of CFEs from mice killed within 12 mo of 
GVHR induction were  oncogenic, the  percentage of oncogenic extracts from 
mice killed  12-15 mo after GVHR induction rose to 75. This contrasts clearly 
with the situation in normal uninjected mice of this low leukemia strain. CFEs 
were prepared from nine male CAF1 mice between the ages of 8 and 18 mo; none 
of these transmitted tumors  to  recipients. 
We have  sought to correlate  oncogenicity in  CFEs from animals with  the 
GVHR with the presence in such extracts of infectious MuLV and CF MuLV 
antigen. Substantial titers of B-tropic MuLV and CF antigen were detected in 
66.7  and  50%,  respectively,  of extracts  from animals killed  11-14 mo  after 
GVHR induction. During the first few months of the administration of parental 
cells, however, MuLV titers were low and CF antigen was absent. There is thus 
a  good correlation late  in  the  GVHR between  the  increased  oncogenicity of 
tissue  extracts  and  their  content  of  substantial  amounts  of  infectious 
MuLV and of CF antigen. 
In  two  separate  experiments,  one  involving CAF~  mice,  the  other  CB6F~ 
mice, CFEs originally derived from a  GVHR mouse have been serially passed 
in vivo. Lymphoreticular tumors of the same type that occur in GVHR mice 
have  developed in  two or  more  successive  transplant  generations  of normal 
syngeneic recipients.  The mean latent period of tumor development has been 
somewhat shortened by serial passage, but is still quite protracted (not less than 
12 mo). However, in one experiment, the incidence of tumors among recipients 
rose from 18.2 to 50 % in two successive transplant generations, and in the other 
experiment, at least 68 % of all recipients in three successive transplant genera- 
tions developed tumors. Such incidence figures make it very unlikely that the 
tumors arose spontaneously.  4 Since all the lymphoreticular tumors tested in the 
serial  passage experiments showed evidence of MuLV infection in the form of 
infectious virus and/or CF antigen and characteristic C-type particles, it seems 
highly probable  that MuLV is  the  agent responsible for the  development of 
lymphoreticular tumors in CAF1 and CB6F~ mice. Taken together,  these  data 
strongly support the concept that activated MuLV causes the lymphoreticular 
tumors which arise in GVHR mice. 
4 In a series of control mice killed in our laboratory at 18 mo of age, 1 of 91 (1.1%) CAF1 
male mice and 6 of 82 (7.3~)  CB6F1 male mice had lymphoreticular tumors. ARMSTRONG,  RUDDLE, LYPMAN, AND  RICHARDS  1175 
The work of Rowe and Hartley and their colleagues (21,  22) has established 
that naturally occurring MuLVs fall into one of two categories with respect to 
their growth in mouse embryo cells of NIH Swiss  (N) or BALB/c (]3) mice. 
"N-tropic" viruses initiate infection 30-1,000  times more efficiently on NIH 
Swiss than on BALB/c mouse embryo cells, while "B-tropic" viruses show  the 
reciprocal pattern. Furthermore, mouse embryo cells of other mouse strains re- 
semble either NIH Swiss or BALB/c mouse embryo cells in their susceptibility 
to infection by either N- or B-tropic virus. The patterns of susceptibility to N- 
or B-tropic virus observed in F1 hybrid and progeny of backcross mice are com- 
patible with a single genetic locus whose allelic genes are dominant for resistance 
to either N- or B-tropic virus (22). The apparent switch from low titers of N- 
tropic virus early in the GVHR to higher titers of B-tropic virus late in  the 
GVHR is of interest. It has been shown (23)  that normal BALB/c mice, which 
are mostly negative for infectious virus before 4 mo of age, yield both N-tropic 
and B-tropic virus as they age. It is possible that the GVHR activates both 
types of virus in the BALB/c hybrids, but that since CAF1 and CB6F1 mice are 
F~ hybrids of two B strains, only the B-tropic virus can achieve titers necessary 
for oncogenicity. Compatibility of host cell and viral tropism may also be an 
important factor in the transforming capacity of the virus. Other evidence (24) 
suggests that the efficiency with which MuLV is transmitted from cell to cell, 
and thus the ease with which an activated virus can become established in a 
given host, may be governed by other genetic factors in addition to the N-B 
lOCUS. 
Although the MuLV activated during the GVHR in CAF1 and CB6F~ mice 
undoubtedly has oncogenic potential in its host, that potential is clearly quite 
low. The incidence of lymphoreticular tumors in CAF, GVHR animals is only 
27 % at 12 mo, rising to 55 % at 18 mo (7). CFEs from GVHR animals induce 
tumors only after a protracted latent period (15 mo and more) and then usually 
in only a minority of littermate recipients. Serial passage of CFEs in syngeneic 
mice has somewhat enhanced the oncogenicity of the activated virus in that the 
percent of littermate recipients developing tumors has increased, and the latent 
period has  been  shortened.  Other MuLV-host combinations  are  much more 
efficient in terms of in vivo tumorigenesis. The AKR strain,  for example, is 
chronically infected from birth with MuLV, which causes lymphocytic leukemia 
in 92 % of the animals, after an average latent period of 8 mo (25). However, 
like the other high leukemia mouse strain,  C58,  the AKR strain is of the N 
type and its virus is N-tropic (22). This suggests that the N  allele of the N-B 
locus might also be a major determinant of spontaneous oncogenesis. 
It is of interest that C-type particles with the structural characteristics of 
MuLV were so readily seen in both the CB6F1 tumors examined by electron 
microscopy in the present study. Previous attempts (7) to detect such particles 
in the tissues of CAF~ GVHR mice, both before and after the development of 
tumors, failed despite a fastidious search through many specimens. However, 1176  IMMUNOLOGICAL ACTIVATION OF  MURINE  LEUKEMIA  VIRUS 
in a recent study, 5 CAFI mice were selected for examination by electron micros- 
copy early in the GVHR and only if infectious virus could be detected in their 
tissues by the XC test. Under these circumstances,  C-type particles were seen 
in a majority of the animals. The CB6F, GVHR mice have not been previously 
examined for C-type particles, but it is noteworthy that the XC test was positive 
in  both  the  animals  we  studied  with  the  electron  microscope.  A  number of 
lymphoreticular tumors arising in (BALB/cJ X  SJL/J)Ft hybrid mice after the 
administration of BALB/c spleen cells have also been examined in our labora- 
tory., 6 but only a very" occasional C-type particle has been seen. 
What are the possible mechanisms whereby viral activation and oncogenesis 
occur in the GVHR, in strains where MuLV normally exists in inactive or un- 
expressed form? It has been suggested that immunosuppression associated with 
the GVHR could permit virus-infected and/or virus-transformed cells to persist 
and multiply unchecked. However, experiments reported elsewherd have shown 
that in this particular GVHR model, cellular immune mechanisms that are prob- 
ably  responsible  for the  rejection  of virus-infected  and/or  virus-transformed 
cells remain intact,  and may even be enhanced. An alternative explanation is 
that the very large pool of lymphocytes stimulated during the GVHR present 
the virus with a previously nonpermissive population of cells, in which it can 
now replicate, and which it can also transform. It has been shown that tuber- 
culin-sensitized lymphocytes activated in vitro by tuberculin-purified protein 
derivative are able to replicate Newcastle disease virus and vesicular stomatitis 
virus, whereas unstimulated cells do not (26). There is now some evidence that 
such  a  mechanism is important in  the development of GVHR-associated tu- 
mors. This comes from the observation that in vitro stimulation of lymphocytes 
resulting from the cocultivation of normal BALB/cJ and CAF1 mice is associ- 
ated with release of MuLV (27). 
The demonstration that a normally inactive or unexpressed oncogenic virus 
can be activated by an immunological disturbance such as the GVHR, and that 
the activated virus is responsible for subsequent tumor development, has im- 
portant  implications.  There  is  currently  considerable  interest  in  the  role  of 
viruses in cancer induction in man (28). Huebner and Todaro have  suggested 
that the cells of many, and perhaps all, vertebrates contain in their genome the 
information for producing oncogenic RNA virus, and that this  "virogene" has 
been acquired during the course of evolution, being transmitted vertically from 
cell to cell and parent to offspring. In their view, the occurrence of most cancers 
is a natural biological event determined by spontaneous or induced derepression 
Andr6-Schwartz, J., R. S. Schwartz, M. S. Hirsch, S. M. Phillips, and P. H. Black. Ac- 
tivation  of leukemia viruses by graft-versus-host and mixed lymphocyte culture reaction: 
electron microscopic evidence of C-type particles. Manuscript submitted for publication. 
6 Heywood, P. Unpublished data. 
7 Ruddle, N. H., M. Y. K. Armstrong, and F. F.  Richards. Cellular immunity in mice 
developing graft-versus-host reaction-associated tumors. Manuscript submitted for publica- 
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of the "oncogene," that portion of the virogene which codes for a transforming 
protein (29). The oncogene theory has gained support from the observation that 
5-iododeoxyuridine and  5-bromodeoxyuridine induce  synthesis  of  MuLV  in 
previously negative mouse embryo cell lines (30,  31). Activation of MuLV in 
the GVHR could represent an analogous in vivo situation. 
The GVHR mouse model may have a counterpart in certain forms of human 
cancer where a viral etiology is likely. One such cancer is Burkitt's lymphoma 
(32) which occurs predominantly in children in geographic locations where the 
one single common factor so far identified is the occurrence of holoendemic ma- 
laria. Burkitt's lymphoma is also associated with a herpes-like DNA virus, the 
Epstein-Barr  virus.  Lymphoreticular hyperplasia  is  an  important  effect  of 
chronic malaria and may provide Epstein-Barr virus with just those "lympho- 
blastoid" cells that it requires for its growth. The ability of Epstein-Barr virus 
to promote rapid and continued proliferation of lymphocytes in culture (33) and 
to bring about morphological transformation of human embryo fibroblasts in 
vitro (34) suggest that it may well be oncogenic in vivo. 
SUMMARY 
A  graft-vs.-host reaction  (GVHR)  was  induced  in  young male  CAF~  and 
CB6F1 mice by the administration of BALB/cJ spleen cells.  A  proportion of 
such mice subsequently developed lymphoreticular rumors.  Cell-free extracts 
(CFEs)  prepared from the  reticular tissues  of CAF~ mice killed  at intervals 
after the induction of the GVHR were tested for their capacity to produce the 
same tumors in a litter of syngeneic mice inoculated at birth. 12 of 29 (41.4%) 
such  extracts were positive, causing  lymphoreticular tumors in  one or more 
littermate recipients. The positive CFEs canle from donors killed at all stages of 
the GVHR, from tumor-bearing mice as well as from non-tumor-bearing mice. 
However, whereas less than 30%  of CFEs from mice killed within  12 mo of 
GVHR induction were oncogenic, the incidence of oncogenic extracts from mice 
killed 12-15 mo after GVHR induction rose to 75 %. None of the CFEs  pre- 
pared from nine normal uninjected male CAF1 mice killed between the ages of 8 
and 18 mo transmitted tumors to recipients. CFEs prepared from CAF~ mice 
with the GVHR were tested for infectious routine leukemia virus (MuLV) using 
the XC assay and also for complement-fixing (CF) group-specific MuLV anti- 
gen. Substantial fiters of B-tropic MuLV and CF antigen were detected in at 
least half the extracts from mice killed 11-14 mo after GVHR induction. During 
the first few months of GVHR induction, MuLV titers were low and CF antigen 
was absent. Neither infectious MuLV nor CF antigen were detected in CFEs 
prepared from normal control mice.  Serially passed  CFEs originating from a 
CB6F1 GVHR-induced RCN caused similar tumors in successive generations of 
syngeneic recipient mice. These lymphoreticular tumors were shown to contain 
infectious MuLV,  CF  MuLV  antigen,  and  C-type particles.  These  data  to- 
gether provide evidence that MuLV is activated during the GVHR and that it 
is responsible for the eventual development of lymphoreticular tumors. 1178  IMMUNOLOGICAL  ACTIVATION OF  MURINE LEUKEMIA VIRUS 
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